Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Shuchao Qin, Ming Liu, Yi Xia, Luomengjia Dai, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Xiao Lu, Wei Xu, Lei Fan, Jianyong Li

Blood (2024) 144 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2024-204881

Published: 2024

Journal Articles

Exploration of the Specific Mechanism of EGR2 Hotspot Mutation Mediating the Upregulation of Galectin-1 Expression in the Progression of CLL Following Treatment with BTK Inhibitor

Xiao Lu, Yeqin Sha, Xinyu Song, Luomengjia Dai, Ziyuan Zhou, Hanning Tang, Yi Miao, Shuchao Qin, Yi Xia, Tonglu Qiu, Lei Fan, Jianyong Li, Huayuan Zhu

Blood (2024) 144 (Supplement 1): 4612.

https://doi.org/10.1182/blood-2024-207729

Published: 2024

Journal Articles

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Shenmiao Yang, Huayuan Zhu, Ru Feng, Xutao Guo, Ting Niu, Jian-Qing Mi, Zhenling Li, Qianqian Ju, Liru Wang, Yujun Dong, Bingjie Wang, Liang Wang, Wanling Sun, Fang Fang, Liping Su, Yu Zhao, Xiaojun Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 6773.

https://doi.org/10.1182/blood-2024-206560

Published: 2024

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Yi Xia, Shuchao Qin, Wei Wu, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2023-188925

Published: 2023

Journal Articles

A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma

Huayuan Zhu, Luomengjia Dai, Yeqin Sha, Xiao Lu, Siqi Qian, Tonglu Qiu, Yi Miao, Yi Xia, Shuchao Qin, Ziyuan Zhou, Wei Wu, Lei Fan, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2023-189681

Published: 2023

Journal Articles

Multi-Center Study of COVID-19 Infection in Elderly Patients with Lymphoma: On Behalf of Jiangsu Cooperative Lymphoma Group (JCLG)

Blood (2023) 142 (Supplement 1): 6269.

https://doi.org/10.1182/blood-2023-182889

Published: 2023

Journal Articles

Loss of DDX3X Function Promotes CLL Progression By Facilitating NOTCH1 mRNA Translation

Yi Miao, Jing Zhang, Huayuan Zhu, Jianyong Li

Blood (2023) 142 (Supplement 1): 83.

https://doi.org/10.1182/blood-2023-188872

Published: 2023

Journal Articles

Preliminary Safety, Pharmacological and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor

Shuhua Yi, Jie Jin, Keshu Zhou, Huayuan Zhu, Kate Ma, Rili Jiang, Weige Wang, Bin Zhang, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6149.

https://doi.org/10.1182/blood-2023-182558

Published: 2023

Journal Articles

Significance of the Rhoa G17V Mutation Detected By Ddpcr in Diagnostic and Monitor of Angioimmunoblastic T-Cell Lymphoma

Yi Miao, Siqi Qian, Xiao Lu, Tonglu Qiu, Shuchao Qin, Yi Xia, Lei Fan, Jianyong Li, Huayuan Zhu

Blood (2023) 142 (Supplement 1): 6083.

https://doi.org/10.1182/blood-2023-182617

Published: 2023

Journal Articles

A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Huayuan Zhu, Yi Xia, Yi Miao, Shuchao Qin, Wei Wu, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2023) 142 (Supplement 1): 6554.

https://doi.org/10.1182/blood-2023-189110

Published: 2023

Journal Articles

High Prevalence of MYD88 and CD79B Mutations and PD-L1 Alterations in Bone Marrow Large B Cell Lymphoma Associated with Hemophagocytic Lymphohistiocytosis

Wenyu Shi, Yi Miao, Yu Shi, Huayuan Zhu, Jianyong Li

Blood (2023) 142 (Supplement 1): 6106.

https://doi.org/10.1182/blood-2023-188651

Published: 2023

Journal Articles

Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Rui Jiang, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Hui Jin, Jianyong Li

Blood (2022) 140 (Supplement 1): 6985–6987.

https://doi.org/10.1182/blood-2022-169720

Published: 2022

Journal Articles

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Hui Shen, Jingyan Qiu, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2022) 140 (Supplement 1): 4164–4165.

https://doi.org/10.1182/blood-2022-170815

Published: 2022

Journal Articles

Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2022) 140 (Supplement 1): 4117–4118.

https://doi.org/10.1182/blood-2022-170985

Published: 2022

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 study)

Huayuan Zhu, Li Wang, Lei Fan, Fei Li, Yulan Zhou, Wei Xu, Jianyong Li

Blood (2022) 140 (Supplement 1): 12421–12422.

https://doi.org/10.1182/blood-2022-169381

Published: 2022

Journal Articles

Single-Cell RNA Sequencing Reveals the Characteristics of High Proliferating Tumor Cells in Btki-Resistant Progression to Richter Transformation and Accelerated CLL

Yeqin Sha, Shuchao Qin, Yi Miao, Rui Jiang, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Hui Jin, Jianyong Li, Huayuan Zhu

Blood (2022) 140 (Supplement 1): 6992–6993.

https://doi.org/10.1182/blood-2022-169907

Published: 2022

Journal Articles

The Interim Efficacy of Epigenetic Priming Regimen with Azacytidine and Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Kaiyang Ding, Xiao Shi, Haiyan Yang, Lei Cao, Xiaoli Zhao, Hailing Liu, Wei Wu, Xiaoyan Zhang, Li Wang, Wei Xu, Huayuan Zhu, Jianyong Li, Lei Fan

Blood (2021) 138 (Supplement 1): 2461.

https://doi.org/10.1182/blood-2021-150523

Published: 2021

Journal Articles

Zanubrutinib, Lenalidomide Plus R-CHOP (ZR 2 -CHOP) As the First-Line Treatment for Diffused Large B-Cell Lymphoma (DLBCL)

Huayuan Zhu, Yeqin Sha, Wei Wu, Jingyan Qiu, Yilian Yang, Chen Peng, Chongyang Ding, Zhen Wang, Lei Fan, Wei Xu, Jianyong Li

Blood (2021) 138 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2021-150510

Published: 2021

Journal Articles

Autologous Stem Cell Transplantation after Conditioning with Chidamide Plus Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (Chi-BEAC) for Treatment of High-Risk and Relapsed/Refractory Aggressive Lymphoma: Multi-Center, Single-Arm, Open-Label Phase II Clinical Trial

Wei Xu, Yi Xia, Li Wang, Kaiyang Ding, Huayuan Zhu, Maogui Hu, Hua Yin, Jiazhu Wu, Haorui Shen, Jin-Hua Liang, Jianyong Li

Blood (2021) 138 (Supplement 1): 660.

https://doi.org/10.1182/blood-2021-147093

Published: 2021

Journal Articles

Single-Cell Sequencing Technology Reveals the Heterogeneity of the Immune Microenvironment and Key Molecules of Drug Resistance in Angioimmunoblastic T-Cell Lymphoma

Hui Jin, Lei Fan, Xueying Lu, Lei Cao, Zijuan Wu, Luqiao Wang, Huayuan Zhu, Jianyong Li

Blood (2021) 138 (Supplement 1): 1322.

https://doi.org/10.1182/blood-2021-152354

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Exploration of the Specific Mechanism of EGR2 Hotspot Mutation Mediating the Upregulation of Galectin-1 Expression in the Progression of CLL Following Treatment with BTK Inhibitor

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma

Multi-Center Study of COVID-19 Infection in Elderly Patients with Lymphoma: On Behalf of Jiangsu Cooperative Lymphoma Group (JCLG)

Loss of DDX3X Function Promotes CLL Progression By Facilitating NOTCH1 mRNA Translation

Preliminary Safety, Pharmacological and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor

Significance of the Rhoa G17V Mutation Detected By Ddpcr in Diagnostic and Monitor of Angioimmunoblastic T-Cell Lymphoma

A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

High Prevalence of MYD88 and CD79B Mutations and PD-L1 Alterations in Bone Marrow Large B Cell Lymphoma Associated with Hemophagocytic Lymphohistiocytosis

Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia

Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 study)

Single-Cell RNA Sequencing Reveals the Characteristics of High Proliferating Tumor Cells in Btki-Resistant Progression to Richter Transformation and Accelerated CLL

The Interim Efficacy of Epigenetic Priming Regimen with Azacytidine and Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Zanubrutinib, Lenalidomide Plus R-CHOP (ZR 2 -CHOP) As the First-Line Treatment for Diffused Large B-Cell Lymphoma (DLBCL)

Autologous Stem Cell Transplantation after Conditioning with Chidamide Plus Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (Chi-BEAC) for Treatment of High-Risk and Relapsed/Refractory Aggressive Lymphoma: Multi-Center, Single-Arm, Open-Label Phase II Clinical Trial

Single-Cell Sequencing Technology Reveals the Heterogeneity of the Immune Microenvironment and Key Molecules of Drug Resistance in Angioimmunoblastic T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only